Alvotech

Yahoo Finance • 5 days ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines i... Full story

Yahoo Finance • 5 days ago

Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair

REYKJAVÍK OG LONDON, BRETLANDI (6. OKTÓBER 2025) Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að Lyfjastofnun Evrópu (EMA) hefði tekið til umsagnar umsókn samstarfsaðila félagsins Advanz Pharma um markaðsleyfi fyrir AVT23, fyrirhugaða... Full story

Yahoo Finance • 18 days ago

Sector Update: Health Care Stocks Advance Tuesday Afternoon

Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.2% and the Health Ca PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 19 days ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Me... Full story

Yahoo Finance • 19 days ago

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva, sem bæði innihalda virka e... Full story

Yahoo Finance • 19 days ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco L... Full story

Yahoo Finance • 22 days ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commerciali... Full story

Yahoo Finance • 22 days ago

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech

REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“), samstarfsaðila Alvotech í Japan, leyfi til markaðss... Full story

Yahoo Finance • last month

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23... Full story

Yahoo Finance • last month

Alvotech tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley í New York

Alvotech (NASDAQ: ALVO) tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley, sem haldin verður dagana 8.-10. september nk., í New York. Fundir með fjárfestum verða haldnir þriðjudaginn 9. september og Balaji Pra... Full story

Yahoo Finance • 2 months ago

Alvotech, Advanz Pharma get EU nod for Eylea biosimilar

[Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.] Carl Lokko/iStock via Getty Images * Alvotech (NASDAQ:ALVO [https://seekingalpha.com/symbol/ALVO]) an... Full story

Yahoo Finance • 2 months ago

Alvotech: European Commission Approves Mynzepli As Biosimilar To Eylea

(RTTNews) - Alvotech (ALVO) and Advanz Pharma Holdco announced that the European Commission has approved Mynzepli as a biosimilar to Eylea or aflibercept, in a pre-filled syringe and vial. The centralized marketing authorization is valid i... Full story

Yahoo Finance • 2 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive analytic... Full story

Yahoo Finance • 2 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the compan... Full story

Yahoo Finance • 2 months ago

Alvotech utser Patrik Ling till VP of Investor Relations Scandinavia

REYKJAVIK, ISLAND (20 augusti 2025) — Alvotech (NASDAQ: ALVO), ett globalt bioteknikföretag som specialiserat sig på utveckling och tillverkning av biosimilarer för patienter över hela världen, meddelade idag att Patrik Ling har anslutit s... Full story

Yahoo Finance • 2 months ago

UnitedHealth, Duolingo Lead Market Cap Stock Movers on Monday

Monday’s trading session is showcasing significant movements in stocks across different market capitalizations, with mega-cap UnitedHealth Group (NYSE:UNH) and large-cap Duolingo (NASDAQ:DUOL) standing out among the movers. Here’s a look... Full story

Yahoo Finance • 2 months ago

Alvotech SA (NASDAQ:ALVO) Surpasses Q2 2025 Estimates with Strong Revenue and EPS Growth

ALVOTECH SA (NASDAQ:ALVO [https://www.chartmill.com/stock/quote/ALVO]) REPORTS STRONG Q2 2025 EARNINGS, BEATS REVENUE AND EPS ESTIMATES Alvotech SA, a global biotech company specializing in biosimilar medicines, reported its second-quarte... Full story

Yahoo Finance • 2 months ago

Curious about the stocks that are showing activity after the closing bell on Wednesday?

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER... Full story

Yahoo Finance • 2 months ago

Alvotech birtir uppgjör fyrir fyrstu sex mánuði ársins og kynnir nýjustu áfanga í rekstri félagsins

Yfir 200% aukning á tekjum af sölu lyfja á fyrri helmingi ársins miðað við sama tíma í fyrraAnnar ársfjórðungur sá besti í sögu félagsins hvað varðar handbært fé frá rekstri Nýir samningar um markaðsetningu endurspegla virði lyfja á fyrri... Full story

Yahoo Finance • 2 months ago

S&P Futures Gain as Fed Rate-Cut Bets Firm

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning, extending yesterday’s gains as growing expectations for Federal Reserve interest rate cuts fueled risk-on sentime... Full story